Japan Approves LEQEMBI Pen, First At-Home Alzheimer's Treatment
BIIB sits 60% above its 52-week low of $135.39.
Summary
Japan approved LEQEMBI Pen, the subcutaneous autoinjector form of Biogen and Eisai's Alzheimer's drug lecanemab, for early Alzheimer's disease. This is the third country to approve the SC formulation, following U.S. approval in July 2026 and China in September 2026. The approval enables once-weekly at-home self-administration, reducing clinic visits and infusion burden compared to IV dosing. This expands the commercial opportunity for LEQEMBI in Japan, a key market, and reinforces the drug's global rollout. The approval follows positive Phase 3 Clarity AD data and SC sub-studies showing comparable exposure to IV. Watch for Japan's Central Social Insurance Medical Council listing within 60 days, which will enable self-administration.
At the time of this announcement, BIIB was trading at $216.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.9B. The 52-week trading range was $135.39 to $225.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.